clarithromycin has been researched along with dexlansoprazole in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Miura, M; Sugawara, K; Suzuki, T; Tada, H; Tateishi, T; Uno, T; Yasui-Furukori, N | 1 |
| Hayakari, M; Miura, M; Niioka, T; Suzuki, T; Tateishi, T; Uno, T; Yasui-Furukori, N | 1 |
| Mahachai, V; Prapitpaiboon, H; Vilaichone, RK | 1 |
| Chen, A; Hsu, PI; Hsu, WH; Kuo, CH; Tsay, FW; Wu, DC | 1 |
| Chen, YH; Hsu, PI; Kao, JY; Kao, SS; Kuo, CH; Peng, NJ; Shie, CB; Tsai, KW; Tsai, TJ; Tsay, FW; Wang, HM; Wu, DC | 1 |
1 review(s) available for clarithromycin and dexlansoprazole
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
5 trial(s) available for clarithromycin and dexlansoprazole
| Article | Year |
|---|---|
Effect of clarithromycin on the enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cross-Over Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Dexlansoprazole; Double-Blind Method; Drug Interactions; Enzyme Inhibitors; Genotype; Heterozygote; Homozygote; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Proton Pump Inhibitors; Stereoisomerism | 2005 |
Estimation of the area under the concentration-time curve of racemic lansoprazole by using limited plasma concentration of lansoprazole enantiomers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cross-Over Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dexlansoprazole; Double-Blind Method; Female; Fluvoxamine; Genotype; Half-Life; Humans; Lansoprazole; Male; Models, Biological; Proton Pump Inhibitors; Stereoisomerism | 2008 |
High Efficacy of Levofloxacin-Dexlansoprazole-Based Quadruple Therapy as a First Line Treatment for Helicobacter pylori Eradication in Thailand.
Topics: Anti-Bacterial Agents; Antidiarrheals; Bismuth; Breath Tests; Clarithromycin; Cytochrome P-450 CYP2C19; Dexlansoprazole; Drug Therapy, Combination; Female; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Organometallic Compounds; Prospective Studies; Proton Pump Inhibitors; Salicylates; Thailand | 2015 |
A Pilot Randomized Controlled Study of Dexlansoprazole MR-Based Triple Therapy for Helicobacter Pylori Infection.
Topics: Adult; Aged; Anti-Bacterial Agents; Clarithromycin; Dexlansoprazole; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Pilot Projects; Proton Pump Inhibitors; Rabeprazole; Risk Factors; Stomach Diseases; Treatment Outcome | 2016 |
Equivalent efficacies of reverse hybrid and concomitant therapies in first-line treatment of Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Dexlansoprazole; Drug Administration Schedule; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Treatment Outcome | 2020 |
1 other study(ies) available for clarithromycin and dexlansoprazole
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |